“Antibiotic resistance: understand, innovate, act. »

The search for therapeutic alternatives in the field of antibacterials is a major public health issue and has been identified as a priority, both nationally and internationally. In line with the global action plan to fight against antimicrobial resistance adopted by the WHO in 2015 and the publication in November 2016 of the interministerial roadmap for controlling antimicrobial resistance in France, the government has decided to set up a priority research program (PPR) on antibiotic resistance, endowed with €40 million over ten years. The aim of this call for projects is to stimulate, promote and support the emergence of diagnostic, preventive and therapeutic innovations and to achieve better use of antibiotics.

The PHAG-ONE project receives €2.85 million to develop viruses able to eradicate resistant bacteria to antibiotics.

Phage therapy is a treatment using viruses, called bacteriophages, able to attack specifically bacteria and to destroy them with complete harmlessness for human cells. The PHAG-ONE project is one of the 11 projects selected as part of the call for projects "Antibiotic resistance: understand, innovate, act" led by the National Research Agency (ANR). This priority research program was launched by the government, under the aegis of the General Secretariat for Investment and the ANR, as part of the Future Investment Programs

Phag-One Milestones